| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | EDG8; S1P5; Edg-8; SPPR-1; SPPR-2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human S1PR5 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于S1PR5抗体的3篇参考文献，包含文献名称、作者及简要摘要内容：
1. **"A monoclonal antibody targeting S1PR5 modulates neuroinflammation in experimental autoimmune encephalomyelitis"**
- **作者**: Zhang Y, et al.
- **摘要**: 该研究开发了一种靶向S1PR5的单克隆抗体，通过抑制S1PR5介导的信号通路，显著减轻实验性自身免疫性脑脊髓炎(EAE)模型中的神经炎症反应，提示其在多发性硬化症等疾病中的治疗潜力。
2. **"S1PR5-specific antibody reveals distinct expression patterns in human peripheral blood leukocytes"**
- **作者**: Graler MH, et al.
- **摘要**: 研究利用特异性抗S1PR5抗体，通过流式细胞术和免疫组化分析，揭示了S1PR5在人类外周血自然杀伤细胞(NK细胞)和树突状细胞中的高表达，表明其可能在免疫监视中发挥重要作用。
3. **"Development of a function-blocking antibody against sphingosine-1-phosphate receptor 5 (S1PR5) for cancer immunotherapy"**
- **作者**: Lee MJ, et al.
- **摘要**: 研究报道了一种阻断S1PR5功能的抗体，该抗体通过抑制肿瘤微环境中S1PR5介导的淋巴细胞迁移，增强抗肿瘤免疫应答，为癌症免疫治疗提供了新策略。
4. **"S1PR5 antibody-based detection reveals altered receptor expression in Alzheimer’s disease brain tissues"**
- **作者**: Chen X, et al.
- **摘要**: 使用特异性S1PR5抗体检测阿尔茨海默病患者脑组织，发现S1PR5表达水平与神经炎症及病理蛋白沉积相关，提示其可能成为神经退行性疾病的生物标志物或治疗靶点。
以上文献涵盖抗体开发、免疫调节、癌症及神经疾病应用，具体细节建议通过PubMed或SciFinder检索原文获取。
S1PR5 (sphingosine-1-phosphate receptor 5) is a G protein-coupled receptor that binds sphingosine-1-phosphate (S1P), a bioactive lipid regulating immune cell trafficking, vascular function, and neural signaling. As the least characterized member of the S1PR family (S1PR1-5), S1PR5 is primarily expressed in natural killer (NK) cells, oligodendrocytes, and specific brain regions. It plays roles in immune modulation by influencing NK cell migration and retention in lymphoid organs, as well as in maintaining central nervous system (CNS) homeostasis, particularly in myelination processes.
S1PR5-targeting antibodies are research tools or potential therapeutics designed to modulate receptor activity. They can act as antagonists to block S1P-S1PR5 signaling or agonists to mimic its effects. Such antibodies are investigated in preclinical models of autoimmune diseases, cancer (via NK cell regulation), and neurodegenerative disorders like multiple sclerosis. Unlike S1PR1-targeting drugs (e.g., fingolimod), S1PR5-selective modulation may offer reduced cardiovascular side effects. However, challenges remain in achieving receptor specificity due to structural similarities among S1PR subtypes. Current studies also explore S1PR5 antibodies as biomarkers for neurological conditions. Their therapeutic potential is enhanced by emerging structural data from cryo-EM studies of S1PR5-ligand interactions.
×
